Sterling Bay has recently announced the addition of four new biotech tenants at their revamped scientific research facility located at 2430 N. Halsted in Chicago’s Lincoln Park neighborhood. These new tenants include Seq Biomarque, CeGaT Corporation, EVOQ Therapeutics, and Cyclopure.
Seq Biomarque is a leading research and diagnostic technologies firm that specializes in developing highly sensitive blood-based multi-factor screening and diagnostic tests for Alzheimer’s disease. CeGaT Corporation is making its debut in the U.S., focusing on advancements in genomics and personalized medicine.
EVOQ Therapeutics, spun out of the University of Michigan’s on-campus lab, works to revolutionize autoimmune disease treatment with novel immunotherapies. And Cyclopure specializes in water purification and treatment technologies; they are relocating from Illinois Science + Technology Park to Sterling Bay’s life sciences hub.
The transactions were negotiated by Dave Gloor and Daniella Hemsley on behalf of Sterling Bay while Jonathan Metzland Jack Deroche represented Cyclopure through Cushman & Wakefield. The life sciences hub created by Sterling Bay offers adaptable lab spaces for biotech firms at various stages of growth with flexible options that can accommodate startups as they scale up their operations.
According to Andy Gloor, CEO of Sterling Bay: “We aim to provide a range of spaces that cater to our users’ needs throughout different phases within their growth cycle.” This approach aligns perfectly with Connect CRE ‘s mission – connecting commercial real estate professionals across all sectors nationwide.
